These are PCSK9 inhibitors which block PCSK9 can lower LDL particle concentrations. The LDL receptor (LDLR), on liver and other cell membranes, binds and initiates ingestion of LDL-particles from extracellular fluid into cells, thus reducing LDL particle concentrations. However, when PCSK9 is bound to the LDLR, after the LDLR & LDL particle combination has been ingested, the receptor is degraded and is no longer recycled back to the cell membrane surface to bind and ingest more LDL-particles. If PCSK9 is blocked, more LDLRs are recycled and are present on the surface of cells to remove LDL-particles from the extracellular fluid. Therefore, blocking PCSK9 can lower blood LDL-particle concentrations.
Thanks for this video. It explains a lot about my own lipids lab results.
🙏 I’m glad this video was useful
Very nicely explained sir👌👌🙏🙏
very nice and step by step information
Sir ,what is role of new FDA approved drug for pcks9- alirocumab and evolocumab.
These are PCSK9 inhibitors which block PCSK9 can lower LDL particle concentrations. The LDL receptor (LDLR), on liver and other cell membranes, binds and initiates ingestion of LDL-particles from extracellular fluid into cells, thus reducing LDL particle concentrations. However, when PCSK9 is bound to the LDLR, after the LDLR & LDL particle combination has been ingested, the receptor is degraded and is no longer recycled back to the cell membrane surface to bind and ingest more LDL-particles. If PCSK9 is blocked, more LDLRs are recycled and are present on the surface of cells to remove LDL-particles from the extracellular fluid. Therefore, blocking PCSK9 can lower blood LDL-particle concentrations.